755 related articles for article (PubMed ID: 26089678)
1. Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.
Ment J
Vasc Health Risk Manag; 2015; 11():317-32. PubMed ID: 26089678
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
3. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
4. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Galanis T; Merli GJ
Hosp Pract (1995); 2013 Feb; 41(1):26-36. PubMed ID: 23466965
[TBL] [Abstract][Full Text] [Related]
5. Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation.
Xiong Q; Lau YC; Lip GY
J Comp Eff Res; 2015 Aug; 4(4):367-76. PubMed ID: 26274798
[TBL] [Abstract][Full Text] [Related]
6. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
Alcocer L
Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
[TBL] [Abstract][Full Text] [Related]
7. Novel anticoagulants for stroke prevention in patients with atrial fibrillation.
Jalota A; Scarabelli TM; Saravolatz L; Bakhsh MU; Agrawal P; Jalota R; Chen-Scarabelli C; Fuster V; Halperin J
Cardiovasc Drugs Ther; 2014 Jun; 28(3):247-62. PubMed ID: 24842559
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
9. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
Briere JB; Bowrin K; Coleman C; Fauchier L; Levy P; Folkerts K; Toumi M; Taieb V; Millier A; Wu O
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):27-36. PubMed ID: 30169975
[TBL] [Abstract][Full Text] [Related]
10. Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
Mangiafico RA; Mangiafico M
Curr Med Chem; 2012; 19(27):4688-98. PubMed ID: 22830344
[TBL] [Abstract][Full Text] [Related]
11. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Oertel LB; Fogerty AE
J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
13. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
Deitelzweig S
Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
[TBL] [Abstract][Full Text] [Related]
14. Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
Saliba W
Am J Cardiovasc Drugs; 2015 Oct; 15(5):323-35. PubMed ID: 26055615
[TBL] [Abstract][Full Text] [Related]
15. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Bansal VK; Herzog CA; Sarnak MJ; Choi MJ; Mehta R; Jaar BG; Rocco MV; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):859-868. PubMed ID: 28941763
[TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
17. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L
Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
19. Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation.
Stacy Z; Richter S
Clin Appl Thromb Hemost; 2017 Jan; 23(1):5-19. PubMed ID: 26988835
[TBL] [Abstract][Full Text] [Related]
20. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]